In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry…
By W. Abraham, K. Adams, G. Fonarow, M. Costanzo, R. Berkowitz, T. LeJemtel, M. Cheng, Janet Wynne. Journal of the American College of Cardiology, 2005
743 citations recorded by the source corpus.
Subfields: Biomedical Engineering, Cardiology and Cardiovascular Medicine, Nephrology
View Paper: https://www.semanticscholar.org/paper/32cb273eaa8778ad0a2178354a16ad540baa7076
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Nephrology
Citations in the corpus
- Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction: Prevalence, Therapies, and Outcomes (2012, methodology): “Additional data from ADHERE, including patients with both HF-preserved EF and HFreduced EF, emphasized the adverse effect of inotropes across all populations of heart failure.(23)”
- 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “BNP and NT-proBNP levels improve with treatment of chronic HF (225, 272-274), with lowering of”
- 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “org/ on 12/10/2013 CAD is common in patients with HFpE (592); however, there are no studies to determine the impact of revascularization on symptoms or outcomes specifically in patients with HFpEF.”
- Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. (2007, background): “concern has been raised about the adverse effect of these treatments on long-term clinical outcomes.(10-17) Volume overload remains a major cause of hospitalization and of continued morbidity among hospitalized patients,(18,19) and concern exists regarding the adverse renal impact of diuretic and ot”
- Narrative Review (2012, neutral): “An analysis of the ADHERE registry has shown that short-term inotrope therapy was associated with significantly longer hospital length of stay and higher inhospital mortality compared with short-term vasodilator therapy.(91) Similarly, the Flolan International Randomized Survival Trial (FIRST) demon”
- The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. (2014, background): “This finding has important prognostic implications, as even short-term inotropic support has been associated with increased mortality (47).”